Italy
Population in 2012: | 60.9m |
People newly diagnosed with cancer (excluding NMSC) / yr: | 354,500 |
Age-standardised rate, incidence per 100,000 people/yr: | 278.6 |
Risk of getting cancer before age 75: | 27.4% |
People dying from cancer /yr: | 170,000 |



Cancer Organisations and Resources (16 links)
The site includes details of the animal tumour registry in the Veneto Region, north-eastern Italy. English and Italian language.
Associazione Italiana Contro le Leucemie-Linfomi e Mieloma - Italiana - Translate to English
A socially active non-profit organisation founded in 1969, with over 80 sections throughout Italy. AIL promotes research, provides support and raises awareness of blood diseases.
Associazione Italiana di Oncologia Cervico Cefalica | Italian Head and Neck Oncologic Society - Italiana - English
AIOCC
AIOCC is a medical non-profit membership organization finalized to study and research in the field of head and neck oncology.
Associazione Italiana di Radioterapia Oncologica | Italian Association of Radiation Oncology - Italiana - Translate to English
Associazione Italiana Ematologia Oncologia Pediatrica - Italiana - Translate to English
Associazione Italiana Malati di Cancro | Italian Association of Cancer Patients, relatives and friends - Italiana - Translate to English
AIMaC
Extensive information, videos and resources.
Associazione Italiana per la Lotta al Neuroblastoma | Italian Neuroblastoma Association - Italiana - English
A national association initially founded by parents in 1993.
Associazione Italiana per la Ricerca sull'Anemia di Fanconi onlus | Italian Association for Research on Fanconi Anemia - Italiana - Translate to English
Peer-reviewed open access cancer journal founded by the European Institute of Oncology in Milan
Italian Association for Medical Oncology - Italiana - Translate to English
AIOM
The scientific society for Italian medical oncologists, founded in 1973.
Italian Confederation of Parent Organizations of children and adolescents with cancer. | Italian Confederation of Parent Organizations of children and adolescents with cancer. - Italiana - English
FAIGOP
The federation was founded in 1995 and brought together 20 Parents Associations involved in support for childhood cancer.
Italian Sarcoma Group - Italiana - Translate to English
ISG
Membership based group for health professionals and researchers with an interest in sarcomas. Founded in 1997. The site supports both English and Italian language.
Lega Italiana per la Lotta contro Tumori | Italian League for the Fight Against Cancer - Italiana - Translate to English
A non-profit, volunteer organization involved in cancer education, support, and research.
Mario Negri Gynecologic Oncology Group - Italiana - Translate to English
Multicenter Italian Trias in Ovarian cancer and gynecologic malignancies
MITO
A no-profit association which aims to improve cooperation in the field of Ginecologic Oncology in Italy.
Oncologia per l'Africa ONLUS - Afron | Oncology for Africa Onlus - Italiana - Translate to English
A charity working with health facilities of African countries to develop information programs, prevention and treatment of cancer to improve health conditions and guarantee the right to health.
Cancer Centres: Italy (16 links)
Azienda Ospedaliera Arcispedale S. Maria Nuova - Italiana - English
Includes an Institute of Oncology and Advanced Technology.
Azienda Ospedaliera Universitaria San Martino- IST – Istituto Nazionale per la Ricerca sul Cancro - Italiana - Translate to English
IRCCS
Centro di Riferimento Oncologico - Istituto Nazionale Tumori, Aviano - Italiana - Translate to English
CRO Aviano
Centro di Riferimento Oncologico della Basilicata - Italiana - Translate to English
CROB
Cancer center serving the Basilicata region. Established 1989.
European Institute of Oncology - Italiana - English
IEO
Founded in 1987, one of Italy’s 45 research hospitals and treatment centres.
Fondazione IRCCS Istituto Nazionale dei Tumori - Italiana - Translate to English
Institute for Cancer Research and Treatment
IRCC, Turin
Istituto di Oncologia Molecolare - Italiana - Translate to English
IFOM
Istituto di Ricerche Farmacologiche Mario Negri - Italiana - Translate to English
IRFMN
Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione 'G.Pascale' - Italiana - Translate to English
Istituto Oncologico Veneto - Italiana - Translate to English
IOV
Istituto Scientifico Romagnolo per la Cura dei Tumori - Italiana - Translate to English
Istituto Superiore di Oncologia - Italiana - Translate to English
Istituto Tumori Bari - Italiana - Translate to English
San Raffaele Hospital | San Raffaele Hospital - Italiana - Translate to English
Ospedale San Raffaele; IRCCS
A clinical-scientific University hospital established 1971. Includes departments of Oncohaematology and Medical Oncology.
Latest Research Publications related to Italy
Italian Prostate Biopsies Group: 2016 Updated Guidelines Insights.
Anticancer Res. 2017; 37(2):413-424 [PubMed] Related Publications
MATERIALS AND METHODS: A systematic review of the new data emerging from 2012-2015 was performed by a panel of 14 selected Italian experts in urology, pathology and radiology. The experts collected articles published in the English-language literature by performing a search using Medline, EMBASE and the Cochrane Library database. The articles were evaluated using a systematic weighting and grading of the level of the evidence according to the Grading of Recommendations Assessment, Development and Evaluation framework system.
RESULTS: An initial prostate biopsy is strongly recommended when i) prostate specific antigen (PSA) >10 ng/ml, ii) digital rectal examination is abnormal, iii) multiparametric magnetic resonance imaging (mpMRI) has a Prostate Imaging Reporting and Data System (PIRADS) ≥4, even if it is not recommended. The use of mpMRI is strongly recommended only in patients with previous negative biopsy. At least 12 cores should be taken in each patient plus targeted (fusion or cognitive) biopsies of suspicious area (at mpMRI or transrectal ultrasound). Saturation biopsies are optional in all settings. The optimal strategy for reducing infection complications is still a controversial topic and the instruments to reduce them are actually weak. The adoption of Gleason grade groups in adjunction to the Gleason score when reporting prostate biopsy results is advisable.
CONCLUSION: These updated guidelines and recommendations are intended to assist physicians and patients in the decision-making regarding when and how to perform a prostatic biopsy.
Are gastric hyperplastic polyps an additional manifestation in celiac disease?: Results from a retrospective study.
Medicine (Baltimore). 2017; 96(5):e5923 [PubMed] Free Access to Full Article Related Publications
Sarcopenia predicts reduced survival in patients with hepatocellular carcinoma at first diagnosis.
Ann Hepatol. 2017 Jan-Feb 2017; 16(1):107-114 [PubMed] Related Publications
AIM: To assess the prevalence and influence of sarcopenia on overall survival in a cohort of cirrhotic patients with hepatocellular carcinoma managed in a tertiary center.
MATERIAL AND METHODS: Abdominal computed tomography of 92 consecutive hepatocellular carcinoma cirrhotic patients, enrolled and followed from 2004 to 2014, were retrospectively studied with a software analyzing the cross-sectional areas of muscles at third lumbar vertebra level. Data was normalized for height, skeletal muscle index (SMI) calculated and presence of Sarcopenia measured. Sarcopenia was defined by SMI ≤ 41 cm2/m2 for women and ≤ 53 cm2/m2 for men with body mass index (BMI) ≥ 25, and ≤ 43 cm2/m2 for men and women with BMI < 25, respectively.
RESULTS: Median age at diagnosis was 71.9 years (30.7-86.4) and BMI 24.7 (17.5-36.7), comparable in women 23.1, (17.5-36.7) and men 24.7 (18.4-36.7). A class of CHILD score and BCLC A prevailed (55.4% and 41.3%, respectively); metastatic disease was found in 12% of cases. Sarcopenia was present in 40.2% of cases, mostly in females (62.9%; p = 0.005). Mean overall survival was reduced in sarcopenic patients, 66 (95% CI 47 to 84) vs. 123 (95% CI 98 to 150) weeks (p = 0.001). At multivariate analysis, sarcopenia was a predictor of reduced overall survival, independent of age (p = 0.0027).
CONCLUSIONS: This retrospective study shows high prevalence of sarcopenia among cirrhotic patients with hepatocellular carcinoma. Presence of sarcopenia was identified as independent predictor of reduced overall survival. As easily measurable by CT, sarcopenia should be determined for prognostic purposes in this patient population.
New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group.
Crit Rev Oncol Hematol. 2017; 109:35-41 [PubMed] Related Publications
Scarce information about breast cancer screening: An Italian websites analysis.
Medicine (Baltimore). 2016; 95(50):e5615 [PubMed] Free Access to Full Article Related Publications
In Vitro Protective Effects of Lycium barbarum Berries Cultivated in Umbria (Italy) on Human Hepatocellular Carcinoma Cells.
Biomed Res Int. 2016; 2016:7529521 [PubMed] Free Access to Full Article Related Publications
Polyurethane Implants in 2-Stage Breast Reconstruction: 9-Year Clinical Experience.
Aesthet Surg J. 2017; 37(2):171-176 [PubMed] Related Publications
OBJECTIVES: The authors determined the incidence of CC following 2-stage breast reconstruction using PU foam-covered implants, with and without radiation therapy.
METHODS: The records of 92 patients who received 115 PU implants were retrospectively reviewed. The rates of CC over time were compared for irradiated and nonirradiated groups with a Kaplan-Meier analysis and log-rank test. CC rates also were analyzed with respect to age.
RESULTS: The median follow-up time for patients was 103.3 months. Nine patients experienced unilateral Baker grade III or IV fibrous CC, including 6 patients from the irradiated group and 3 patients from the nonirradiated group. The overall cumulative incidence of CC at 9 years was 8.1%. In the irradiated and nonirradiated groups, the 9-year cumulative incidence was 10.7% and 5.5%, respectively. CC occurred within 3 years in the irradiated group and within 7 years in the nonirradiated group. The incidence of CC appeared to be higher among younger patients.
CONCLUSIONS: Radiation therapy increases the risk of high-grade CC with textured or smooth implants. PU implants are associated with a much lower cumulative incidence of CC following 2-stage breast reconstruction, even when radiotherapy is performed. LEVEL OF EVIDENCE 3.
Glucose-6-phosphate dehydrogenase deficiency and risk of colorectal cancer in Northern Sardinia: A retrospective observational study.
Medicine (Baltimore). 2016; 95(44):e5254 [PubMed] Related Publications
Mutation spectrum of NF1 gene in Italian patients with neurofibromatosis type 1 using Ion Torrent PGM™ platform.
Eur J Med Genet. 2017; 60(2):93-99 [PubMed] Related Publications
Video-assisted thoracic lobectomy for lung cancer in Italy: the 'VATS Group' Project.
Future Oncol. 2016; 12(23s):9-11 [PubMed] Related Publications
Incidence of neuroepithelial primary brain tumors among adult population of Emilia-Romagna Region, Italy.
Neurol Sci. 2017; 38(2):255-262 [PubMed] Related Publications
Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel).
Ann Hematol. 2016; 95(12):1955-1963 [PubMed] Related Publications
Ethics in oncology: principles and responsibilities declared in the Italian Ragusa statement.
Tumori. 2016; 102(6):e25-e27 [PubMed] Related Publications
Posttransplant solid organ malignancies in lung transplant recipients: a single-center experience and review of the literature.
Tumori. 2016; 102(6):574-581 [PubMed] Related Publications
METHODS: A retrospective analysis was conducted of all patients who underwent a lung transplant in the Lung Transplant Program at the University Hospital of Siena, Italy, from 2001 to 2014 (n = 119). Patients' demographics, pretransplant characteristics, immunosuppressive therapy, and infectious factors were recorded.
RESULTS: Nine patients with a median age of 59.0 years (range 50-63) of our cohort developed a solid-organ tumor (7.5%). Most of the patients experienced nonmelanoma skin cancer (44.4%); the others were diagnosed with lung cancer (22.2%), breast cancer (22.2%), and colon-rectal cancer (11.2%). The median time from transplantation to tumor diagnosis was 895.0 days (range 321-2046). No differences in pretransplant characteristics, immunosuppressive therapy, or infectious factors were found between patients who developed solid organ tumors and those who did not.
CONCLUSIONS: The present study confirmed that de novo malignancies are a major issue in lung transplant patients; in particular, skin and lung cancers demonstrated a higher incidence rate. Oncologic treatment of these patients is complex, requiring close collaboration between the transplant team and oncologist. Strict screening programs are key factors for an early diagnosis and to allow for prompt treatment resulting in a better outcome.
Variation in hospital utilization at the end of life for patients with cancer in the Emilia-Romagna region of Italy.
Tumori. 2016; 102(6):614-620 [PubMed] Related Publications
METHODS: We conducted a retrospective, population-level study using administrative data. Patients were included if they died in 2012 and had at least one hospital admission for metastatic or poor-prognosis cancer within 180 days of death. Variations in the use of the hospital, intensive care, and procedures performed were evaluated.
RESULTS: 11,470 patients died with metastatic or poor-prognosis cancer in 2012. Seventy-eight percent of patients were hospitalized in the last month of life while 50.7% of patients died in the hospital. Results varied by local health authority from 38.3% to 69.3%. Of patients who had an ICU stay, 55.1% in the community hospitals and 59.8% in the teaching hospitals were admitted to the ICU on the day of death or the day before death. 7.5% of patients underwent a major procedure in the last 30 days of life.
CONCLUSIONS: The overall high rate, and substantial variation, in hospital care at the end of life offers the RER the opportunity to evaluate if increasing availability of palliative care, along with provider and patient education, could reduce utilization of high-cost hospital care and increase patient and family satisfaction.
New treatment strategies for HIV-positive cancer patients undergoing antiblastic chemotherapy.
Expert Opin Pharmacother. 2016; 17(18):2391-2403 [PubMed] Related Publications
Pre-operative Diagnosis of Pancreatic Neuroendocrine Tumors with Endoscopic Ultrasonography and Computed Tomography in a Large Series.
J Gastrointestin Liver Dis. 2016; 25(3):317-21 [PubMed] Related Publications
METHODS: This was a retrospective analysis of prospectively collected sporadic p-NET cases. All patients underwent both standard multidetector CT study and EUS with fine-needle aspiration (FNA). The final histological diagnosis was achieved on a post-surgical specimen. Chromogranin A (CgA) levels were measured.
RESULTS: A total of 80 patients (mean age: 58 +/- 14.2 years; males: 42) were enrolled. The diameter of functioning was significantly lower than that of non-functioning p-NETs (11.2 +/- 8.5 mm vs 19.8 +/- 12.2 mm; P = 0.0004). The CgA levels were more frequently elevated in non-functioning than functioning pNET patients (71.4% vs 46.9%; P = 0.049). Overall, the CT study detected the lesion in 51 (63.7%) cases, being negative in 26 (68.4%) patients with a tumor =10 mm, and in a further 3 (15%) cases with a tumor diameter =20 mm. CT overlooked the pancreatic lesion more frequently in patients with functioning than non-functioning p-NETs (46.5% vs 24.3%; P = 0.002). EUS allowed a more precise pre-operative tumor measurement, with an overall incorrect dimension in only 9 (11.2%) patients. Of note, the EUS-guided FNA suspected the neuroendocrine nature of tumor in all cases.
CONCLUSIONS: Data of this large case series would suggest that the EUS should be included in the diagnostic work-up in all patients with a suspected p-NET, even when the CT study was negative for a primary lesion in the pancreas.
Single Nucleotide Polymorphisms within the 8Q24 Region are Not Associated with the Risk of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
J Gastrointestin Liver Dis. 2016; 25(3):311-5 [PubMed] Related Publications
METHODS: The study was performed on 117 IPMN cases and 231 controls. Cases were enrolled at the Digestive Endoscopy Unit, Policlinico Agostino Gemelli from January, 2010 to June, 2011, with either a prevalent or incident IPMN diagnosis. Status of SNPs was determined using a StepOne Real-time PCR system (Applied Biosystems) and TaqMan SNP Genotyping Assay™ 40X. Unconditional multiple logistic regression models were used to estimate odds ratios and 95% confidence intervals for the association of selected SNPs and IPMNs.
RESULTS: Cases were more likely to report a 1st degree family history of cancer (p<0.001), as well as heavy smoking (p=0.001) and heavy drinking habits (p<0.001). No significant association was observed between IPMN and selected SNPs. The results were confirmed also when stratified according to any 1st-degree family history of cancer.
CONCLUSION: Patients with IPMN do not have a higher prevalence of SNPs in the human chromosomal region 8q24 in respect to the control population.
Immediate Adverse Reactions to Gadolinium-Based MR Contrast Media: A Retrospective Analysis on 10,608 Examinations.
Biomed Res Int. 2016; 2016:3918292 [PubMed] Free Access to Full Article Related Publications
The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.
Eur J Nucl Med Mol Imaging. 2017; 44(2):215-223 [PubMed] Free Access to Full Article Related Publications
METHODS: Patients treated between 2009 and 2014 for localized EWS and OS, who underwent FDG PET/CT as part of their staging work-up, were included. The relationships between primary tumour SUVmax at baseline (SUV1), SUVmax after induction chemotherapy (SUV2), metabolic response calculated as [(SUV1 - SUV2)/SUV1)] × 100, LDH and ALP and tumour response/survival were analysed. A good response (GR) was defined as tumour necrosis >90 % in patients with OS, and grade II-III Picci necrosis (persitence of microscopic foci only or no viable tumor) in patients with Ewing sarcoma.
RESULTS: The study included 77 patients, 45 with EWS and 32 with OS. A good histological response was achieved in 53 % of EWS patients, and 41 % of OS patients. The 3-year event-free survival (EFS) was 57 % in EWS patients and 48 % OS patients. The median SUV1 was 5.6 (range 0 - 17) in EWS patients and 7.9 (range 0 - 24) in OS patients (p = 0.006). In EWS patients the GR rate was 30 % in those with a high SUV1 (≥6) and 72 % in those with a lower SUV1 (p = 0.0004), and in OS patients the GR rate was 29 % in those with SUV1 ≥6 and 64 % in those with a lower SUV1 (p = 0.05). In the univariate analysis the 3-year EFS was significantly better in patients with a low ALP level (59 %) than in those with a high ALP level (22 %, p = 0.02) and in patients with a low LDH level (62 %) than in those with a high LDH level (37 %, p = 0.004). In EWS patients the 3-year EFS was 37 % in those with a high SUV1 and 75 % in those with a low SUV1 (p = 0.004), and in OS patients the 3-year EFS was 32 % in those with a high SUV1 and 66 % in those with a low SUV1 (p = 0.1). Histology, age and gender were not associated with survival. In the multivariate analysis, SUV1 was the only independent pretreatment prognostic factor to retain statistical significance (p = 0.017). SUV2 was assessed in 25 EWS patients: the median SUV2 was 1.9 (range 1 - 8). The GR rate was 20 % in patients with a high SUV2, and 67 % in those with a low SUV2 (p = 0.02). A good metabolic response (SUV reduction of ≥55 %) was associated with a 3-year EFS of 80 % and a poor metabolic response with a 3-year EFS of 20 % (p = 0.05). In the OS patients the median SUV2 was 2.7 (range 0 - 4.5). Neither SUV2 nor the metabolic response was associated with outcome in OS patients.
CONCLUSION: FDG PET/CT is a useful and noninvasive tool for identifying patients who are more likely to be resistant to chemotherapy. If this finding is confirmed in a larger series, SUV1, SUV2 and metabolic response could be proposed as factors for stratifying EWS patients to identify those with high-grade localized bone EWS who would benefit from risk-adapted induction chemotherapy.
Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy.
Future Oncol. 2017; 13(3):233-248 [PubMed] Related Publications
METHODS: An online survey was conducted in Italy on a population of 329 medical oncologists, 380 GPs and 350 patients.
RESULTS: Most of GPs (n = 291; 76%) claim that follow-up should be provided by the collaboration between GPs and medical oncologists. Most medical oncologists report to have a poor relationship with GPs (n = 151; 46%) or no relationships at all (n = 14; 4%). Most patients believe there is no real collaboration between medical oncologists and GPs (n = 138; 54%).
CONCLUSION: GPs, medical oncologists and patients share the idea that the collaboration between oncologists and GPs for surveillance of cancer survivors is poor and should be improved.
Recommendations for breast imaging follow-up of women with a previous history of breast cancer: position paper from the Italian Group for Mammography Screening (GISMa) and the Italian College of Breast Radiologists (ICBR) by SIRM.
Radiol Med. 2016; 121(12):891-896 [PubMed] Free Access to Full Article Related Publications
Image-guided radiation therapy (IGRT): practical recommendations of Italian Association of Radiation Oncology (AIRO).
Radiol Med. 2016; 121(12):958-965 [PubMed] Related Publications
Does the hospitalization after a cancer diagnosis modify adherence to process indicators of diabetes care quality?
Acta Diabetol. 2016; 53(6):1009-1014 [PubMed] Related Publications
METHODS: Adherence to guideline composite indicator (GCI), a process indicator including one annual assessment of HbA1c and at least two among eye examination, serum lipids measurement and microalbuminuria, was evaluated between years 2011-2012 and 2014-2015 in 158,069 diabetic patients living in Tuscany, Italy, on 1 January 2011 and surviving on 31 December 2015, of whom 661 were hospitalized in index year 2013 for a surgery procedure due to a newly incident cancer. Difference in GCI modification (DELTA_GCI) of these patients was compared with that of diabetic people without cancer, strictly matched for main confounders by means of a propensity score.
RESULTS: In diabetic patients with cancer, GCI adherence increased by about 8 % between years 2011-2012 and 2014-2015. When compared with controls, DELTA_GCI increased by 6 % in cancer group compared with controls (p < 0.05), but any significance was lost after matching the groups by propensity score (3 %; p = NS).
CONCLUSIONS: Our study suggests that a hospitalization for a surgical procedure due to a newly diagnosed cancer does not influence the compliance to a quality process indicator of diabetes care such as GCI.
Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT.
Eur J Nucl Med Mol Imaging. 2017; 44(2):224-233 [PubMed] Related Publications
MATERIALS AND METHODS: Forty-one patients affected by BC underwent FDG PET/CT for restaging purpose. The diagnostic accuracy of visually interpreted FDG PET/CT was assessed compared to histology (n = 8), other diagnostic imaging modalities (contrast-enhanced CT in 38/41 patients and MRI in 15/41) and clinical follow-up (n = 41). Semiquantitative PET values (SUVmax, SUVmean, SUL, MTV, TLG) were calculated using a graph-based method. Progression-free survival (PFS) and overall survival (OS) were assessed by using Kaplan-Meier curves. The risk of progression (hazard ratio, HR) was computed by Cox regression analysis by considering all the available variables.
RESULTS: PET was considered positive in 21 of 41 patients. Of these, recurrent BC was confirmed in 20 (95 %). Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of FDG PET/CT were 87 %, 94 %, 95 %, 85 %, 90 %. AUC was 0.9 (95 %IC 0.8-1). Bayesian positive and negative likelihood ratios were 14.5 and 0.13, respectively. FDG PET/CT findings modified the therapeutic approach in 16 patients (modified therapy in 10 PET-positive patients, watch-and-wait in six PET-negative patients). PFS was significantly longer in patients with negative scan vs. those with pathological findings (85 % vs. 24 %, p < 0.05; HR = 12.4; p = 0.001). Moreover, an unremarkable study was associated with a longer OS (88 % vs. 47 % after 2 years and 87 % vs. 25 % after 3 years, respectively, p < 0.05). Standardized uptake value (SUV)max > 6 and total lesion glycolysis (TLG) > 8.5 were recognized as the most accurate thresholds to predict PFS (2-year PFS 62 % for SUVmax < 6 vs. 15 % for SUVmax > 6, p = 0.018; 2-year PFS 66 % for TLG < 8.5 vs. 18 % for TLG > 8.5, p = 0.09).
CONCLUSION: A very good diagnostic performance for FDG PET/CT was confirmed in patients with suspected recurrent BC. FDG PET/CT allowed for a change in treatment decision in about 40 % of cases and showed an important prognostic value in assessing PFS and OS.
Insulin resistance is associated with the aggressiveness of pancreatic ductal carcinoma.
Acta Diabetol. 2016; 53(6):945-956 [PubMed] Related Publications
METHODS: Prospective observational study of patients admitted to a referral center for pancreatic disease. Insulin resistance was defined as a HOMA-IR value greater than the 66th percentile value of the patients included in this study. Survival was estimated according to Kaplan-Meier and by Cox regression.
RESULTS: Of 296 patients with PDAC, 99 (33 %) met criteria for being classified as insulin resistant at diagnosis. Median follow-up time after diagnosis was 5.27 ± 0.23 years. Patients with insulin resistance received a diagnosis of PDAC at a similar age compared to patients without insulin resistance (67.1 ± 9 vs. 66.8 ± 10 years, p = 0.68), but were more likely to have a cancer stage ≥3 (23.2 vs. 14.2 %, p = 0.053) and a residual disease after surgery (R1 56.4 vs. 38 %; p = 0.007). The median overall survival was 1.3 ± 0.14 and 1.79 ± 0.11 years for the patients with and without insulin resistance, respectively (p = 0.016). Results did not change when patients with diabetes at PDAC diagnosis were excluded from the analysis. Multivariate analysis showed that insulin resistance was independently associated with overall survival.
CONCLUSIONS: Insulin resistance is associated with the aggressiveness of PDAC.
A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.
Future Oncol. 2016; 12(22):2589-2602 [PubMed] Related Publications
The evidence of toxic wastes dumping in Campania, Italy.
Crit Rev Oncol Hematol. 2016; 105:84-91 [PubMed] Related Publications
Mammography and MRI for screening women who underwent chest radiation therapy (lymphoma survivors): recommendations for surveillance from the Italian College of Breast Radiologists by SIRM.
Radiol Med. 2016; 121(11):834-837 [PubMed] Related Publications
Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions.
Br J Radiol. 2016; 89(1065):20150981 [PubMed] Article available free on PMC after 01/09/2017 Related Publications
METHODS: Between May 1998 and December 2011, 2237 patients with early-stage prostate cancer from 11 Italian community and academic hospitals were treated with iodine-125 ((125)I) or palladium-103 LDR-BT as monotherapy and followed up for at least 2 years. (125)I seeds were implanted in 97.7% of the patients: the mean dose received by 90% of target volume was 145 Gy; the mean target volume receiving 100% of prescribed dose (V100) was 91.1%. Biochemical failure-free survival (BFFS), disease-specific survival (DSS) and overall survival (OS) were estimated using Kaplan-Meier method. Log-rank test and multivariable Cox regression were used to evaluate the relationship of covariates with outcomes.
RESULTS: Median follow-up time was 65 months. 5- and 7-year DSS, OS and BFFS were 99 and 98%, 94 and 89%, and 92 and 88%, respectively. At multivariate analysis, the National Comprehensive Cancer Network score (p < 0.0001) and V100 (p = 0.09) were correlated with BFFS, with V100 effect significantly different between patients at low risk and those at intermediate/high risk (p = 0.04). Short follow-up and lack of toxicity data represent the main limitations for a global evaluation of LDR-BT.
CONCLUSION: This first multicentre Italian report confirms LDR-BT as an excellent curative modality for low-/intermediate-risk prostate cancer.
ADVANCES IN KNOWLEDGE: Multidisciplinary teams may help to select adequately patients to be treated with brachytherapy, with a direct impact on the implant quality and, possibly, on outcome.